JP2020531487A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020531487A5 JP2020531487A5 JP2020510099A JP2020510099A JP2020531487A5 JP 2020531487 A5 JP2020531487 A5 JP 2020531487A5 JP 2020510099 A JP2020510099 A JP 2020510099A JP 2020510099 A JP2020510099 A JP 2020510099A JP 2020531487 A5 JP2020531487 A5 JP 2020531487A5
- Authority
- JP
- Japan
- Prior art keywords
- pyridin
- pyrrolo
- trifluoromethyl
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 43
- 150000003839 salts Chemical class 0.000 claims 40
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 18
- 206010028980 Neoplasm Diseases 0.000 claims 12
- 125000001072 heteroaryl group Chemical group 0.000 claims 11
- 229910052739 hydrogen Inorganic materials 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 11
- 229910052757 nitrogen Inorganic materials 0.000 claims 10
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 9
- -1 cyano, phenyl Chemical group 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 7
- 125000005843 halogen group Chemical group 0.000 claims 6
- 125000004076 pyridyl group Chemical group 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 229940079593 drug Drugs 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 125000001153 fluoro group Chemical group F* 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 4
- 230000002950 deficient Effects 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 239000001301 oxygen Substances 0.000 claims 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 4
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 3
- 125000001544 thienyl group Chemical group 0.000 claims 3
- 125000006677 (C1-C3) haloalkoxy group Chemical group 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- QVXZGMUKOWYSOX-UHFFFAOYSA-N 4-(1H-pyrazolo[3,4-b]pyridin-4-yl)-6-[2-(trifluoromethyl)piperidin-1-yl]-1H-pyridin-2-one Chemical compound N1N=CC=2C1=NC=CC=2C1=CC(NC(=C1)N1C(CCCC1)C(F)(F)F)=O QVXZGMUKOWYSOX-UHFFFAOYSA-N 0.000 claims 2
- CSXOYNVGINDZNB-UHFFFAOYSA-N 4-(1H-pyrrolo[2,3-b]pyridin-4-yl)-6-[2-(trifluoromethyl)phenyl]-1H-pyridin-2-one Chemical compound N1C=CC=2C1=NC=CC=2C1=CC(NC(=C1)C1=C(C=CC=C1)C(F)(F)F)=O CSXOYNVGINDZNB-UHFFFAOYSA-N 0.000 claims 2
- DOJFVPVHXQICAN-UHFFFAOYSA-N 4-(1H-pyrrolo[2,3-b]pyridin-4-yl)-6-[2-(trifluoromethyl)piperidin-1-yl]-1H-pyridin-2-one Chemical compound N1C=CC=2C1=NC=CC=2C1=CC(NC(=C1)N1C(CCCC1)C(F)(F)F)=O DOJFVPVHXQICAN-UHFFFAOYSA-N 0.000 claims 2
- JDKCFBIRILXMFJ-UHFFFAOYSA-N 4-(1H-pyrrolo[2,3-b]pyridin-4-yl)-6-[3-(trifluoromethyl)morpholin-4-yl]-1H-pyridin-2-one Chemical compound N1C=CC=2C1=NC=CC=2C1=CC(NC(=C1)N1C(COCC1)C(F)(F)F)=O JDKCFBIRILXMFJ-UHFFFAOYSA-N 0.000 claims 2
- CXYDPZLJNIQRAZ-UHFFFAOYSA-N 4-(2-cyclopropyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-6-[4-ethylsulfonyl-2-(trifluoromethyl)piperazin-1-yl]-1H-pyridin-2-one Chemical compound C1(CC1)C1=CC=2C(=NC=CC=2C2=CC(NC(=C2)N2C(CN(CC2)S(=O)(=O)CC)C(F)(F)F)=O)N1 CXYDPZLJNIQRAZ-UHFFFAOYSA-N 0.000 claims 2
- IBNJRAAEJIHRLO-UHFFFAOYSA-N 4-(2-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-6-[2-(trifluoromethyl)piperidin-1-yl]-1H-pyridin-2-one Chemical compound CC1=CC=2C(=NC=CC=2C2=CC(NC(=C2)N2C(CCCC2)C(F)(F)F)=O)N1 IBNJRAAEJIHRLO-UHFFFAOYSA-N 0.000 claims 2
- SDFBGSCILLFDMY-UHFFFAOYSA-N 4-(2-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-6-morpholin-4-yl-1H-pyridin-2-one Chemical compound CC1=CC=2C(=NC=CC=2C2=CC(NC(=C2)N2CCOCC2)=O)N1 SDFBGSCILLFDMY-UHFFFAOYSA-N 0.000 claims 2
- AINQHQYRXCJWMT-UHFFFAOYSA-N 4-(2-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-6-pyridin-3-yl-1H-pyridin-2-one Chemical compound CC1=CC=2C(=NC=CC=2C2=CC(NC(=C2)C=2C=NC=CC=2)=O)N1 AINQHQYRXCJWMT-UHFFFAOYSA-N 0.000 claims 2
- INUVCRPQYQBTTA-UHFFFAOYSA-N 4-[2-(5-methylthiophen-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl]-6-[3-(trifluoromethyl)morpholin-4-yl]-1H-pyridin-2-one Chemical compound CC1=CC=C(S1)C1=CC=2C(=NC=CC=2C2=CC(NC(=C2)N2C(COCC2)C(F)(F)F)=O)N1 INUVCRPQYQBTTA-UHFFFAOYSA-N 0.000 claims 2
- PUNDGYRIKMMQHI-UHFFFAOYSA-N 6-(2-chlorophenyl)-4-(2-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyridin-2-one Chemical compound ClC1=C(C=CC=C1)C1=CC(=CC(N1)=O)C1=C2C(=NC=C1)NC(=C2)C PUNDGYRIKMMQHI-UHFFFAOYSA-N 0.000 claims 2
- KUHXRVPOFWEIIL-UHFFFAOYSA-N 6-(2-chlorophenyl)-4-(2-pyridin-3-yl-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyridin-2-one Chemical compound ClC1=C(C=CC=C1)C1=CC(=CC(N1)=O)C1=C2C(=NC=C1)NC(=C2)C=1C=NC=CC=1 KUHXRVPOFWEIIL-UHFFFAOYSA-N 0.000 claims 2
- IBWQEYYDUJEVFR-UHFFFAOYSA-N 6-(2-chlorophenyl)-4-[2-(1,3-oxazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyridin-2-one Chemical compound ClC1=C(C=CC=C1)C1=CC(=CC(N1)=O)C1=C2C(=NC=C1)NC(=C2)C1=CN=CO1 IBWQEYYDUJEVFR-UHFFFAOYSA-N 0.000 claims 2
- WWHGOOFSNVJOAU-UHFFFAOYSA-N 6-(2-phenylpyrrolidin-1-yl)-4-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyridin-2-one Chemical compound C1(=CC=CC=C1)C1N(CCC1)C1=CC(=CC(N1)=O)C1=C2C(=NC=C1)NC=C2 WWHGOOFSNVJOAU-UHFFFAOYSA-N 0.000 claims 2
- FPZSPEGMNPCQHE-UHFFFAOYSA-N 6-(3-methylpyridin-4-yl)-4-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyridin-2-one Chemical compound CC=1C=NC=CC=1C1=CC(=CC(N1)=O)C1=C2C(=NC=C1)NC=C2 FPZSPEGMNPCQHE-UHFFFAOYSA-N 0.000 claims 2
- LRTZISIKPSKAIP-UHFFFAOYSA-N 6-[2-(trifluoromethyl)piperidin-1-yl]-4-[2-[5-(trifluoromethyl)pyridin-3-yl]-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyridin-2-one Chemical compound FC(C1N(CCCC1)C1=CC(=CC(N1)=O)C1=C2C(=NC=C1)NC(=C2)C=1C=NC=C(C=1)C(F)(F)F)(F)F LRTZISIKPSKAIP-UHFFFAOYSA-N 0.000 claims 2
- SCKYJZZLWPCYAC-UHFFFAOYSA-N 6-[2-(trifluoromethyl)piperidin-1-yl]-4-[2-[6-(trifluoromethyl)pyridin-3-yl]-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyridin-2-one Chemical compound FC(C1N(CCCC1)C1=CC(=CC(N1)=O)C1=C2C(=NC=C1)NC(=C2)C=1C=NC(=CC=1)C(F)(F)F)(F)F SCKYJZZLWPCYAC-UHFFFAOYSA-N 0.000 claims 2
- LDLMFSXKVWKENB-UHFFFAOYSA-N 6-[3-(trifluoromethyl)morpholin-4-yl]-4-[2-[3-(trifluoromethyl)phenyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyridin-2-one Chemical compound FC(C1N(CCOC1)C1=CC(=CC(N1)=O)C1=C2C(=NC=C1)NC(=C2)C1=CC(=CC=C1)C(F)(F)F)(F)F LDLMFSXKVWKENB-UHFFFAOYSA-N 0.000 claims 2
- DNRNHHBDLRQHAU-UHFFFAOYSA-N 6-[4-[(4-fluorophenyl)methylsulfonyl]-2-(trifluoromethyl)piperazin-1-yl]-4-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyridin-2-one Chemical compound FC1=CC=C(C=C1)CS(=O)(=O)N1CC(N(CC1)C1=CC(=CC(N1)=O)C1=C2C(=NC=C1)NC=C2)C(F)(F)F DNRNHHBDLRQHAU-UHFFFAOYSA-N 0.000 claims 2
- VAWHMYMAEPEZTK-UHFFFAOYSA-N 6-[4-ethylsulfonyl-2-(trifluoromethyl)piperazin-1-yl]-4-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyridin-2-one Chemical compound C(C)S(=O)(=O)N1CC(N(CC1)C1=CC(=CC(N1)=O)C1=C2C(=NC=C1)NC=C2)C(F)(F)F VAWHMYMAEPEZTK-UHFFFAOYSA-N 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000032612 Glial tumor Diseases 0.000 claims 2
- 206010018338 Glioma Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 208000036142 Viral infection Diseases 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 125000001207 fluorophenyl group Chemical group 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 125000002971 oxazolyl group Chemical group 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- KDDZUAZEHFIWMN-UHFFFAOYSA-N 4-(1H-pyrazolo[3,4-b]pyridin-4-yl)-6-[2-(trifluoromethyl)phenyl]-1H-pyridin-2-one Chemical compound N1N=CC=2C1=NC=CC=2C1=CC(NC(=C1)C1=C(C=CC=C1)C(F)(F)F)=O KDDZUAZEHFIWMN-UHFFFAOYSA-N 0.000 claims 1
- UHLMTCFPIOAJRK-UHFFFAOYSA-N 4-(2-cyclopropyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-6-[2-(trifluoromethyl)phenyl]-1H-pyridin-2-one Chemical compound C1(CC1)C1=CC=2C(=NC=CC=2C2=CC(NC(=C2)C2=C(C=CC=C2)C(F)(F)F)=O)N1 UHLMTCFPIOAJRK-UHFFFAOYSA-N 0.000 claims 1
- NYYFCAZTWFWZRD-UHFFFAOYSA-N 4-[2-[4-ethylsulfonyl-2-(trifluoromethyl)piperazin-1-yl]-6-oxo-1H-pyridin-4-yl]-1H-pyrrolo[2,3-b]pyridine-2-carbonitrile Chemical compound C(C)S(=O)(=O)N1CC(N(CC1)C=1NC(C=C(C=1)C1=C2C(=NC=C1)NC(=C2)C#N)=O)C(F)(F)F NYYFCAZTWFWZRD-UHFFFAOYSA-N 0.000 claims 1
- JOVIYZVQVRVMNU-UHFFFAOYSA-N 4-[2-oxo-6-[2-(trifluoromethyl)phenyl]-1H-pyridin-4-yl]-1H-pyrrolo[2,3-b]pyridine-2-carbonitrile Chemical compound O=C1NC(=CC(=C1)C1=C2C(=NC=C1)NC(=C2)C#N)C1=C(C=CC=C1)C(F)(F)F JOVIYZVQVRVMNU-UHFFFAOYSA-N 0.000 claims 1
- NCBUSDZFMYRPKX-UHFFFAOYSA-N 6-[4-ethylsulfonyl-2-(trifluoromethyl)piperazin-1-yl]-4-(2-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyridin-2-one Chemical compound C(C)S(=O)(=O)N1CC(N(CC1)C1=CC(=CC(N1)=O)C1=C2C(=NC=C1)NC(=C2)C)C(F)(F)F NCBUSDZFMYRPKX-UHFFFAOYSA-N 0.000 claims 1
- GJZVFKVARNDTAZ-UHFFFAOYSA-N 6-[4-methylsulfonyl-2-(trifluoromethyl)piperazin-1-yl]-4-(1H-pyrazolo[3,4-b]pyridin-4-yl)-1H-pyridin-2-one Chemical compound CS(=O)(=O)N1CC(N(CC1)C1=CC(=CC(N1)=O)C1=C2C(=NC=C1)NN=C2)C(F)(F)F GJZVFKVARNDTAZ-UHFFFAOYSA-N 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- 230000005784 autoimmunity Effects 0.000 claims 1
- 230000008512 biological response Effects 0.000 claims 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims 1
- 125000000068 chlorophenyl group Chemical group 0.000 claims 1
- 150000004696 coordination complex Chemical class 0.000 claims 1
- 125000004966 cyanoalkyl group Chemical group 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000003667 hormone antagonist Substances 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 201000003733 ovarian melanoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229910052697 platinum Inorganic materials 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022198545A JP2023021277A (ja) | 2017-08-23 | 2022-12-13 | アザインドリルピリドンおよびジアザインドリルピリドン化合物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17187519.8 | 2017-08-23 | ||
| EP17187519 | 2017-08-23 | ||
| PCT/EP2018/072785 WO2019038384A1 (en) | 2017-08-23 | 2018-08-23 | AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022198545A Division JP2023021277A (ja) | 2017-08-23 | 2022-12-13 | アザインドリルピリドンおよびジアザインドリルピリドン化合物 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2020531487A JP2020531487A (ja) | 2020-11-05 |
| JP2020531487A5 true JP2020531487A5 (enExample) | 2021-09-30 |
| JPWO2019038384A5 JPWO2019038384A5 (enExample) | 2022-10-20 |
| JP7199738B2 JP7199738B2 (ja) | 2023-01-06 |
Family
ID=59686871
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020510099A Active JP7199738B2 (ja) | 2017-08-23 | 2018-08-23 | アザインドリルピリドンおよびジアザインドリルピリドン化合物 |
| JP2022198545A Ceased JP2023021277A (ja) | 2017-08-23 | 2022-12-13 | アザインドリルピリドンおよびジアザインドリルピリドン化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022198545A Ceased JP2023021277A (ja) | 2017-08-23 | 2022-12-13 | アザインドリルピリドンおよびジアザインドリルピリドン化合物 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US11498919B2 (enExample) |
| EP (2) | EP4001278A1 (enExample) |
| JP (2) | JP7199738B2 (enExample) |
| KR (1) | KR102731945B1 (enExample) |
| CN (3) | CN116589462A (enExample) |
| AU (1) | AU2018321135B2 (enExample) |
| CA (1) | CA3072861A1 (enExample) |
| CY (1) | CY1124818T1 (enExample) |
| DK (1) | DK3672967T3 (enExample) |
| ES (1) | ES2902346T3 (enExample) |
| HR (1) | HRP20211999T1 (enExample) |
| HU (1) | HUE057818T2 (enExample) |
| IL (3) | IL302355A (enExample) |
| LT (1) | LT3672967T (enExample) |
| PL (1) | PL3672967T3 (enExample) |
| PT (1) | PT3672967T (enExample) |
| RS (1) | RS62785B1 (enExample) |
| SI (1) | SI3672967T1 (enExample) |
| SM (1) | SMT202100718T1 (enExample) |
| TW (2) | TWI785101B (enExample) |
| WO (1) | WO2019038384A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7199738B2 (ja) * | 2017-08-23 | 2023-01-06 | スプリント バイオサイエンス アクティエボラーグ | アザインドリルピリドンおよびジアザインドリルピリドン化合物 |
| JP2023553807A (ja) | 2020-11-25 | 2023-12-26 | デシフェラ・ファーマシューティカルズ，エルエルシー | 抗ウイルス活性のｖｐｓ３４阻害剤 |
| WO2022115562A1 (en) | 2020-11-25 | 2022-06-02 | Deciphera Pharmaceuticals, Llc | Morpholino derivatives as vsp34 inhibitors for use in the treatment of a viral infection |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1154024B (it) * | 1982-09-22 | 1987-01-21 | Lepetit Spa | Derivati pridinici e procedimento per la loro produzione |
| RU2435769C2 (ru) | 2005-05-20 | 2011-12-10 | Вертекс Фармасьютикалз Инкорпорейтед | Пирролопиридины, полезные в качестве ингибиторов протеинкиназы |
| EP2320895A2 (en) * | 2008-07-03 | 2011-05-18 | Exelixis, Inc. | Cdk modulators |
| JP2013525354A (ja) | 2010-04-19 | 2013-06-20 | アッヴィ・インコーポレイテッド | ピロロピリジン系キナーゼ阻害薬 |
| EA201390917A1 (ru) | 2010-12-21 | 2013-12-30 | Новартис Аг | Дигетероарильные соединения в качестве ингибиторов vps34 |
| HUE024504T2 (en) | 2010-12-23 | 2016-01-28 | Sanofi Sa | Pyrimidine derivatives, a process for their preparation and their use in medicine |
| GB201120317D0 (en) | 2011-11-24 | 2012-01-04 | Queen Mary & Westfield College | Screening method |
| CN103450152B (zh) | 2012-06-04 | 2015-11-18 | 济南海乐医药技术开发有限公司 | 基于吲唑、吲哚或氮杂吲唑、氮杂吲哚的双芳基脲类结构抗肿瘤药物 |
| FR2992314B1 (fr) | 2012-06-22 | 2015-10-16 | Sanofi Sa | Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique |
| TN2016000270A1 (en) | 2014-01-14 | 2017-10-06 | Millennium Pharm Inc | Heteroaryls and uses thereof. |
| JP2017502092A (ja) * | 2014-01-14 | 2017-01-19 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | ヘテロアリール及びその使用 |
| MA39823A (fr) | 2014-04-03 | 2018-01-09 | Janssen Pharmaceutica Nv | Dérivés de pyridine macrocyclique |
| MA39822A (fr) | 2014-04-03 | 2018-02-06 | Janssen Pharmaceutica Nv | Dérivés de pyrimidine bicycle |
| CA3015045A1 (en) | 2016-02-19 | 2017-08-24 | Sprint Bioscience Ab | 6-aryl-4-morpholin-1-ylpyridone compounds useful for the treatment of cancer and diabetes |
| US11179399B2 (en) | 2016-02-19 | 2021-11-23 | Sprint Bioscience Ab | 6-heterocyclyl-4-morpholin-4-ylpyridine-2-one compounds useful for the treatment of cancer and diabetes |
| JP7199738B2 (ja) * | 2017-08-23 | 2023-01-06 | スプリント バイオサイエンス アクティエボラーグ | アザインドリルピリドンおよびジアザインドリルピリドン化合物 |
-
2018
- 2018-08-23 JP JP2020510099A patent/JP7199738B2/ja active Active
- 2018-08-23 DK DK18759307.4T patent/DK3672967T3/da active
- 2018-08-23 IL IL302355A patent/IL302355A/en unknown
- 2018-08-23 CN CN202310536658.3A patent/CN116589462A/zh active Pending
- 2018-08-23 EP EP21196341.8A patent/EP4001278A1/en not_active Withdrawn
- 2018-08-23 RS RS20211605A patent/RS62785B1/sr unknown
- 2018-08-23 TW TW107129491A patent/TWI785101B/zh not_active IP Right Cessation
- 2018-08-23 AU AU2018321135A patent/AU2018321135B2/en active Active
- 2018-08-23 CN CN201880054872.2A patent/CN111247144B/zh active Active
- 2018-08-23 SI SI201830500T patent/SI3672967T1/sl unknown
- 2018-08-23 HR HRP20211999TT patent/HRP20211999T1/hr unknown
- 2018-08-23 US US16/638,727 patent/US11498919B2/en active Active
- 2018-08-23 KR KR1020207006930A patent/KR102731945B1/ko active Active
- 2018-08-23 EP EP18759307.4A patent/EP3672967B1/en active Active
- 2018-08-23 HU HUE18759307A patent/HUE057818T2/hu unknown
- 2018-08-23 SM SM20210718T patent/SMT202100718T1/it unknown
- 2018-08-23 PL PL18759307T patent/PL3672967T3/pl unknown
- 2018-08-23 TW TW111140665A patent/TW202325708A/zh unknown
- 2018-08-23 CN CN202310536605.1A patent/CN116589461A/zh active Pending
- 2018-08-23 LT LTEPPCT/EP2018/072785T patent/LT3672967T/lt unknown
- 2018-08-23 ES ES18759307T patent/ES2902346T3/es active Active
- 2018-08-23 WO PCT/EP2018/072785 patent/WO2019038384A1/en not_active Ceased
- 2018-08-23 CA CA3072861A patent/CA3072861A1/en active Pending
- 2018-08-23 PT PT187593074T patent/PT3672967T/pt unknown
-
2020
- 2020-02-20 IL IL272792A patent/IL272792B/en unknown
-
2022
- 2022-01-03 CY CY20221100001T patent/CY1124818T1/el unknown
- 2022-04-25 IL IL292482A patent/IL292482B2/en unknown
- 2022-10-11 US US18/045,605 patent/US20230322772A1/en not_active Abandoned
- 2022-12-13 JP JP2022198545A patent/JP2023021277A/ja not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7014765B2 (ja) | ピラゾロ化合物及びその使用 | |
| KR101985984B1 (ko) | 키나아제 저해제로서의 벤조니트릴 유도체 | |
| JP2020531488A5 (enExample) | ||
| AU2013266110C1 (en) | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators | |
| CN104302626B (zh) | 4,4-二取代的-1,4-二氢嘧啶及其作为治疗乙型肝炎的药物的用途 | |
| CN114846005A (zh) | Shp2抑制剂及其应用 | |
| JP2014500308A (ja) | Ｖｐｓ３４阻害剤としてのビヘテロアリール化合物 | |
| CA2515197A1 (en) | Pyrazolopyridine derivates | |
| Xiao et al. | Biologic-like in vivo efficacy with small molecule inhibitors of TNFα identified using scaffold hopping and structure-based drug design approaches | |
| JP2019505594A5 (enExample) | ||
| JP2023021316A (ja) | ピリジンアミン－ピリドンおよびピリミジンアミン－ピリドン化合物 | |
| RU2018131775A (ru) | 6-арил-4-морфолин-1-илпиридоны, пригодные для лечения рака или диабета | |
| JP2009529047A5 (enExample) | ||
| JP2019514878A5 (enExample) | ||
| JP2019505595A5 (enExample) | ||
| RU2018131766A (ru) | 6-гетероциклил-4-морфолин-4-илпиридин-2-оны, пригодные для лечения рака и диабета | |
| KR20010083055A (ko) | 글리코겐 신타제 키나제 3의 억제제 | |
| KR20160049003A (ko) | 항증식성 화합물 | |
| RU2018134981A (ru) | Конъюгаты, содержащие ингибиторы RIPK2 | |
| CA3000548A1 (en) | Pyrimido- or pyridopyridone compound and use as a cyclin-dependent kinase inhibitor | |
| KR20140107421A (ko) | Pi3k의 활성 또는 기능의 억제제의 용도 | |
| JP2020531487A5 (enExample) | ||
| JP2020523309A5 (enExample) | ||
| JP2023021277A5 (enExample) | ||
| JP2018508553A5 (enExample) |